Fig. 9

Flow cytometry analysis of phospho and total STAT1 in CD3 + lymphocytes from SLE-LN- and SLE-LN + patients. A Prominent proportions of total STAT1 + or p-STAT1 + double-positive lymphocytes were collected from three LN- and three LN + patients were underwent stimulation for 48 h with 200 ng/mL IFN-\(\upbeta\) in the presence or absence of 200 nM Tofacitinib. B Representative histograms of the levels of p-STAT1 and total STAT1 in LN- and LN + lymphocytes treated, as described in (A). The unstimulated cell populations are represented by the solid black lines, whereas the cell populations that were treated with IFN-β and IFN-β + Tofacitinib were denoted by the solid and dashed red lines, respectively. Histograms that were gray-filled depict negative controls (FMO with isotypes). C Comparative statistical evaluation of p-STAT1 and total STAT1 relative MFI in B. Bar graphs show the fold change MFI of p-STAT1 in IFN-\(\upbeta\)-stimulated CD3 + T cells with or without JAKi Tofacitinib between LN- and LN + patients. The results were found to be statistically significant using an unpaired t-test, and the data are presented as mean ± SEM. D The percentages of p-STAT1 + /STAT1 + double positive T cells (CD3 +) from LN- and LN + patients with or without IFN-\(\upbeta\) stimulation in the presence or absence of Tofacitinib. An unpaired t-test was employed to assess the difference between the two groups, and statistical bar graphs with mean ± SEM were utilized for presenting the quantitative results